Several authors have proposed that GSK-3β plays a key role in AD pathogenesis in part because of this tau kinase activity (Hooper et al., 2008; Lauretti et al., 2020; Takashima, 2006), and GSK-3 inhibitors have been shown to have beneficial effects in AD models (Griebel et al., 2019; Hu et al., 2009; Morales-Garcia et al., 2012; Serenó et al., 2009). The gene discussed is GSK3B; the disease is Alzheimer disease.